Biomarker Strategies to Enhance Early-Phase Drug Development
Selecting the right biomarkers early in drug development can provide critical insights into drug activity, safety, and therapeutic response. By integrating biomarker strategies into early-phase studies, sponsors can optimize study design, support patient selection, demonstrate target engagement, and make more informed go/no-go decisions.
What You'll Learn:
- Key biomarker categories and their roles in assessing drug response, safety, and efficacy.
- Disease-specific biomarker strategies for CNS disorders, immuno-oncology, ophthalmology, and metabolic diseases.
- Biomarker considerations across therapeutic modalities, including small molecules, large molecules, and cell and gene therapies.
- Best practices for biomarker selection and fit-for-purpose validation to support reliable data and regulatory requirements.
- How integrated biomarker strategies, bioanalysis, and clinical expertise can support more efficient studies and confident development decisions.
Biomarkers by Disease Indication
Different treatments may require distinct biomarkers when the therapy acts on a unique biological mechanism, target, or pathway. Selecting the appropriate biomarker for your program is essential for robust data collection and analysis.
Multiplex biomarker panels allow for measurement of multiple proteins, cytokines, or metabolites from a single biological sample. These panels accelerate programs by providing comprehensive, multi-pathway insights into target engagement, PD, and early toxicity.
Operationalizing Biomarker Selection
The right biomarker strategy can translate promising biological signals into reliable, decision-enabling tools that can be used across discovery, clinical trials, and regulatory interactions. Such a strategy requires a structured approach that integrates scientific validation, analytical rigor, and clinical relevance.
In early-phase drug development, exploratory biomarkers are often assessed at the nonclinical phase, and only some with predictive outcomes are selected for later phases.
How Altasciences Can Help
Make faster, more confident drug development decisions with integrated biomarker strategies that deliver reliable data and actionable insights from nonclinical through early-phase clinical development. At Altasciences, we bring together biomarker strategy, advanced bioanalysis, and clinical expertise through our Altasciences Acceleration Platform, providing sponsors with a single, coordinated team, rapid turnaround of high-quality data, and seamless continuity across development stages.
Our capabilities span biomarker selection, fit-for-purpose assay validation, advanced bioanalytical technologies, and integrated clinical trial design and conduct. With CLIA-certified laboratories, expertise in complex biomarkers, intensive PK/PD sampling, model-informed drug development, and in-house regulatory support, we help sponsors generate reliable, regulatory-ready data to guide critical development decisions.
Explore all issues of The Altascientist in our Resource Center.